Beam Therapeutics Inc.
NASDAQ:BEAM
Overview | Financials
Company Name | Beam Therapeutics Inc. |
Symbol | BEAM |
Currency | USD |
Price | 23.3 |
Market Cap | 1,929,370,480 |
Dividend Yield | 0% |
52-week-range | 20.84 - 49.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. John M. Evans M.B.A. |
Website | https://www.beamtx.com |
An error occurred while fetching data.
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD